Abstract
Age-related macular degeneration (AMD) affects predominantly individuals during the sixth decade of life and is the commonest cause of visual impairment and irreversible blindness in the Western world. There is no medical treatment for AMD and only a very small number of subjects with late stage disease are amenable to a palliative and minimally effective laser photocoagulation therapy. The molecular mechanism underling AMD is not fully understood and is the major obstacle in the development of aetiologic and prophylactic treatments. However, the genes responsible for certain rare retinal degenerative diseases (with pathological features similar to those of AMD) have been discovered. This helps in the understanding of the pathogenetic mechanism of AMD and provides a source of potential therapeutic targets. Furthermore, the new ocular drug delivery systems that provide a means to overcome the systemic adverse effects of potentially effective drugs and allow the use of those drugs with narrow therapeutic in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
